Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | AOC2 | O75106 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | ATF4 | P18848 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23049719 | 1.00 | CTSL (0.34) | CTSLPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL23049716 | 1.00 | CTSL (0.34) | CTSLPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8809657 | 0.88 | KAT2B (0.35) | PDE4DPDE4APDE4BPDE4CAOC2 | |
| SCHEMBL17517935 | 0.85 | CTSL (0.36) | CTSLPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL27921573 | 0.84 | — | — | |
| SCHEMBL8196504 | 0.81 | CTSL (0.34) | CTSLPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL24186291 | 0.81 | CTSL (0.34) | CTSLPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8230175 | 0.81 | PDE4D (0.38) | CTSLPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13351557 | 0.81 | PDE4D (0.38) | CTSLPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13351589 | 0.81 | PDE4D (0.38) | CTSLPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839665-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| EP-2673287-A1 | AMINO STATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | Merck Patent GmbH (DE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107153-A1 | AMINO STATIN DERIVATIVESFOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSB, CTSZ | CTSL 4/4885PDE4D 2385/4885PDE4A 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.